HIGH-AFFINITY DOPAMINE REUPTAKE INHIBITORS AS POTENTIAL COCAINE ANTAGONISTS - A STRATEGY FOR DRUG DEVELOPMENT

被引:90
作者
ROTHMAN, RB
机构
[1] Unit on Receptor Studies, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20892
关键词
D O I
10.1016/0024-3205(90)90466-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The addictive and euphorogenic effects of cocaine are thought to result primarily from inhibition of dopamine reuptake. Although the potency of cocaine-like drugs as inhibitors of DA reuptake is highly correlated with their potency as reinforcers in animals, several potent DA reuptake blockers (bupropion, nomifensine, benztropine, and mazindol) have not been reported to produce addiction or euphoria in humans. Based on these observations in humans, DA reuptake inhibitors are classified into two groups; type 1 blockers, which produce addiction and euphoria, and type 2 blockers, which do not. Given that type 1 and type 2 blockers act at the same site (the DA transporter), the author suggests that the type 2 agents may antagonize the effects of cocaine, and might prove useful in the treatment of cocaine addiction. © 1990.
引用
收藏
页码:PL17 / PL21
页数:5
相关论文
共 16 条
[2]  
BERGER P, 1989, LANCET, V1, P283
[3]  
BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150
[4]  
BIANCHINE JR, 1980, GOODMAN GILMANS PHAR, P484
[5]  
CHAIT LD, 1987, J PHARMACOL EXP THER, V242, P777
[6]  
DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
[7]   NEUROCHEMICAL INTERACTIONS OF COCAINE WITH DOPAMINERGIC SYSTEMS [J].
GALLOWAY, MP .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1988, 9 (12) :451-454
[8]   MAZINDOL, A NEW NON-AMPHETAMINE ANOREXIGENIC AGENT [J].
HADLER, AJ .
JOURNAL OF CLINICAL PHARMACOLOGY AND NEW DRUGS, 1972, 12 (11-1) :453-&
[9]  
MADRAS BK, 1989, J PHARMACOL EXP THER, V251, P131
[10]   NOMIFENSINE, IMIPRAMINE AND PLACEBO IN DEPRESSED OUTPATIENTS [J].
RICKELS, K ;
WEISE, CC ;
SANDLER, K ;
SCHLESS, A ;
ZAL, M ;
NORSTAD, N .
INTERNATIONAL PHARMACOPSYCHIATRY, 1982, 17 :73-88